On August 7, 2026, Christopher Viehbacher, a director of Braveheart Bio, Inc. ($BRVE), acquired 83,333 shares of the company's common stock in an open-market transaction. The shares were purchased at a price of $18.00 each, producing a total trade value of $1,499,994. The transaction was disclosed in a Form 4 filing submitted to the Securities and Exchange Commission on the same calendar day the trade was executed.
The purchase was classified as an open-market transaction, meaning the shares were bought on the public market rather than obtained through the exercise of stock options, the vesting of restricted stock units, or other equity compensation arrangements that are common in insider filings. Following the August 7 acquisition, Viehbacher's reported holdings in Braveheart Bio stood at 609,519 shares. The Form 4 filing stated that the shares were held directly, and the report did not describe any offsetting sales, option exercises, or derivative transactions by the filer on the same date.
Viehbacher serves on the Braveheart Bio board in the role of director. The August 7 purchase is the only Form 4 transaction attributed to Viehbacher across the full universe of publicly traded companies captured in the insider-transaction database. It also stands as the sole insider trade on record for Braveheart Bio. During the period covered by the dataset, no other directors, executive officers, or ten-percent beneficial owners of the company have filed open-market purchases or sales for $BRVE.
Braveheart Bio, Inc., which trades under the ticker symbol $BRVE, does not have a sector classification, industry group assignment, or market capitalization figure populated in the database as of the filing date. Historical daily stock price records—including open, high, low, close, and volume data—were similarly unavailable for the $BRVE ticker. As a result, the $18.00 per-share purchase price cannot be placed in the context of the stock's recent trading range or volume patterns.
A review of congressional trading disclosures compiled under the STOCK Act found no transactions in $BRVE shares. Neither members of the United States House of Representatives nor the Senate have reported any purchases or sales of Braveheart Bio stock, according to the database of politician filings maintained under the Act.
Because the Form 4 was submitted on August 7—the same calendar day as the trade—there was no delay between the transaction date and the date of public disclosure. SEC regulations generally require insiders to report open-market transactions on Form 4 within two business days of execution. The accession number assigned to the SEC filing was 0001470831-26-000801.